EMERYVILLE, CA, USA, August 30, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018.
The presentation details are listed below and are accessible on the 4th Annual CAR-TCR Summit website:
Presentation Title: Case Report of Regression of Metastatic Liver Cancer After ET140202 T-Cell Therapy
Session Title: Late Breaking Abstracts
Date & Time: Wednesday, September 5, 2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport Hotel & World Trade Center
Presentation Title: Improvement of Safety in T-cell Immunotherapies for the Treatment of Cancer
Session Title: Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time: Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location: Seaport Hotel & World Trade CenterAbout
EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biopharmaceutical company focused on developing novel T-cell therapies that harness the evolutionary power of the immune system. Its core technology platforms center around its proprietary ARTEMIS™ T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
CONTACTS:
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
natalie.liu@eurekainc.com
or
Stern Investor Relations
Julie Seidel
212-362-1200
julie@sternir.com
